10 Best Get Rich Quick Stocks to Buy Now

4. COMPASS Pathways plc (NASDAQ:CMPS)

Upside potential as of July 8, 2025: 359.54%

Beta (5Y Monthly): 2.25

ARK Invest’s ETFs, led by Cathie Wood, disclosed their daily trades on Thursday with the purchase of 125,491 shares of COMPASS Pathways plc (NASDAQ:CMPS), worth around $424,159. This transaction adds to the consistent buys in CMPS in the last few days, implying confidence in the company’s prospects.

Just recently, COMPASS Pathways plc (NASDAQ:CMPS) announced the success of its Phase 3 COMP005 trial for COMP360 in meeting its primary endpoint in patients with treatment-resistant depression. As the results outlined, even a single dose of 25 mg COMP360 led to a statistically significant reduction in symptom severity in contrast to placebo at week 6.

The company’s future looks equally promising, with the management working to discuss the preliminary COMP005 data with the U.S. Food and Drug Administration. Although there is no update regarding the review of the results yet, COMPASS Pathways plc (NASDAQ:CMPS) expects to reveal 26-week data for COMP005, after the participants have passed the initial stage, by the end of 2026.

COMPASS Pathways plc (NASDAQ:CMPS) is a London-based biotechnology company that specializes in mental health across the United States and the UK. Founded in 2020, the company is committed to making evidence-based innovation in mental health accessible to all.